Royal Bank of Canada Reiterates "Outperform" Rating for Beigene (NASDAQ:ONC)

Royal Bank of Canada reaffirmed their outperform rating on shares of Beigene (NASDAQ:ONC - Free Report) in a research note released on Monday,Benzinga reports. They currently have a $312.00 price target on the stock.

Other research analysts also recently issued reports about the company. JMP Securities set a $348.00 price target on Beigene in a report on Friday, February 28th. Macquarie raised their price target on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Guggenheim reissued a "buy" rating on shares of Beigene in a report on Wednesday, April 16th. Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and raised their target price for the stock from $207.00 to $320.00 in a report on Monday, March 3rd. Finally, Sanford C. Bernstein set a $259.00 target price on shares of Beigene in a research note on Thursday, March 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $318.88.

Beigene Stock Up 0.1 %

Beigene stock traded up $0.13 during trading hours on Monday, hitting $255.77. The stock had a trading volume of 180,351 shares, compared to its average volume of 478,851. The stock has a 50-day simple moving average of $248.16. The company has a market cap of $25.30 billion, a PE ratio of -31.04, a P/E/G ratio of 7.73 and a beta of 0.49. Beigene has a 12-month low of $141.31 and a 12-month high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.

Beigene (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1.13 billion during the quarter, compared to analysts' expectations of $1.09 billion. On average, research analysts expect that Beigene will post -5.82 EPS for the current fiscal year.

Insider Buying and Selling at Beigene

In related news, insider Xiaodong Wang sold 41,760 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $261.28, for a total transaction of $10,911,052.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Xiaobin Wu sold 30,654 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $240.74, for a total transaction of $7,379,643.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,146,048 shares of company stock valued at $295,198,300. Insiders own 6.62% of the company's stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.